Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate whether 18F-FDG PET/CT-based prognostic model of diffuse large B-cell lymphoma can predict disease progression
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Peking University Cancer Hospital & Institute
NCT06852638 · Renal Cancer, Renal Clear Cell Carcinoma, and more
NCT06528301 · Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), and more
NCT06093841 · Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, and more
NCT05406401 · Lymphoma, Large B-Cell, Diffuse (DLBCL)
NCT03293173 · Lymphoma, Large B-Cell, Diffuse
Peking University Cancer Hospital
Beijing, Beijing Municipality
Peking University Cancer Hospital
Beijing
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions